Tags

Type your tag names separated by a space and hit enter

Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia.
Expert Opin Investig Drugs. 2002 Mar; 11(3):125-41.EO

Abstract

Rosuvastatin is a synthetic enantiomer that is hepatoselective, relatively hydrophilic and has minimal metabolism via the cytochrome P450 3A4 system (similar to pravastatin). Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The majority of HMG-CoA reductase inhibitory activity in plasma is associated with the parent rosuvastatin compound. In a Phase II study, rosuvastatin across a dose range of 1 - 80 mg lowered low-density lipoprotein cholesterol (LDL-C) by 34 - 65%. Phase III trials have demonstrated greater reductions in LDL-C for rosuvastatin compared to atorvastatin as well as greater increases in high-density lipoprotein cholesterol (HDL-C). The drug appears to be well tolerated at all doses up to 80 mg/day. A starting dose of 10 mg will reduce LDL-C by approximately 50%, which should adequately treat most patients to within the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) goals.

Authors+Show Affiliations

Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA. mdavidson@protocare.com

Pub Type(s)

Comparative Study
Corrected and Republished Article
Journal Article
Review

Language

eng

PubMed ID

12769127

Citation

Davidson, Michael H.. "Rosuvastatin: a Highly Efficacious Statin for the Treatment of Dyslipidaemia." Expert Opinion On Investigational Drugs, vol. 11, no. 3, 2002, pp. 125-41.
Davidson MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002;11(3):125-41.
Davidson, M. H. (2002). Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opinion On Investigational Drugs, 11(3), 125-41.
Davidson MH. Rosuvastatin: a Highly Efficacious Statin for the Treatment of Dyslipidaemia. Expert Opin Investig Drugs. 2002;11(3):125-41. PubMed PMID: 12769127.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. A1 - Davidson,Michael H, PY - 2003/5/29/pubmed PY - 2003/6/24/medline PY - 2003/5/29/entrez SP - 125 EP - 41 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 11 IS - 3 N2 - Rosuvastatin is a synthetic enantiomer that is hepatoselective, relatively hydrophilic and has minimal metabolism via the cytochrome P450 3A4 system (similar to pravastatin). Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The majority of HMG-CoA reductase inhibitory activity in plasma is associated with the parent rosuvastatin compound. In a Phase II study, rosuvastatin across a dose range of 1 - 80 mg lowered low-density lipoprotein cholesterol (LDL-C) by 34 - 65%. Phase III trials have demonstrated greater reductions in LDL-C for rosuvastatin compared to atorvastatin as well as greater increases in high-density lipoprotein cholesterol (HDL-C). The drug appears to be well tolerated at all doses up to 80 mg/day. A starting dose of 10 mg will reduce LDL-C by approximately 50%, which should adequately treat most patients to within the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) goals. SN - 1354-3784 UR - https://www.unboundmedicine.com/medline/citation/12769127/Rosuvastatin:_a_highly_efficacious_statin_for_the_treatment_of_dyslipidaemia_ L2 - https://medlineplus.gov/cholesterolmedicines.html DB - PRIME DP - Unbound Medicine ER -